Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Open Total Pancreatectomy With Modified Cattell-Imanaga Reconstruction: How Do We Do It?

World journal of surgery·2026

Same author

"A dual-applanation physical model to improve accuracy in goldmann tonometry by accounting for corneal biomechanics".

Frontiers in bioengineering and biotechnology·2026

Same author

Targeting Macular Pigment in Intermediate Age-Related Macular Degeneration: Oral Supplementation Versus Transscleral Iontophoresis in a Prospective Pilot Study.

Journal of clinical medicine·2026

Same author

Optical coherence tomography biomarkers in patients with diabetic macular edema treated with dexamethasone implants.

Survey of ophthalmology·2026

Same author

Long term risk of recurrence of ptosis repair: implications for surgical counseling and follow-up.

Frontiers in ophthalmology·2026

Same author

Hypertensive retinopathy in pre-eclampsia and its association with disease severity and neonatal outcomes: A retrospective cohort study.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026

Search research articles

Related Experiment Video

Updated: Jan 8, 2026

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

Aflibercept 8 mg in Neovascular AMD-A Fast-Drying Anti-VEGF Drug: A Prospective Morpho-Functional Pilot Study.

Michele Rinaldi¹, Gilda Cennamo², Marina Concilio^1,3

¹Eye Clinic, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University, Via Pansini n 5, 80131, Naples, Italy.

Ophthalmology and Therapy

|December 13, 2025

Summary

Higher dose aflibercept (8 mg) significantly improved outcomes in neovascular age-related macular degeneration (nAMD) patients compared to the standard 2 mg dose. This suggests 8 mg aflibercept offers faster anatomical and functional recovery in nAMD.

Keywords:

AMD Aflibercept Anti-VEGF Intravitreal injections MPOD Microperimetry SD-OCT

More Related Videos

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

Related Experiment Videos

Last Updated: Jan 8, 2026

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

Area of Science:

Ophthalmology
Retinal Diseases
Pharmacology

Background:

Neovascular age-related macular degeneration (nAMD) poses a significant challenge to vision.
Current treatments aim to inhibit vascular endothelial growth factor (VEGF).
Aflibercept is a key therapeutic agent in nAMD management.

Purpose of the Study:

To compare early anatomical and functional outcomes of 8 mg aflibercept versus 2 mg aflibercept in treatment-naïve nAMD.
To evaluate the efficacy of a higher aflibercept dose for nAMD.
To explore macular pigment optical density (MPOD) as a biomarker for retinal health.

Main Methods:

Prospective observational study with 30 treatment-naïve nAMD patients.
Patients received either 2 mg or 8 mg intravitreal aflibercept.
Evaluations included SD-OCT, microperimetry, and MPOD at baseline, 2, and 4 months.

Main Results:

The 8 mg group showed greater reduction in central macular thickness (CMT) and improved best-corrected visual acuity (BCVA).
Significant improvements in retinal sensitivity, MPOD, and reduced bivariate contour ellipse area (BCEA) were observed in the 8 mg group.
A faster drying rate was noted in the 8 mg group during the initial 2 months.

Conclusions:

Intravitreal aflibercept 8 mg demonstrated superior short-term anatomical and functional benefits over the 2 mg dose in nAMD.
The 8 mg dose appears effective for achieving more rapid results in nAMD treatment.
MPOD shows potential as a novel biomarker for assessing retinal functional response in nAMD.